预约演示
更新于：2025-05-16
Penehyclidine hydrochloride
盐酸戊乙奎醚
更新于：2025-05-16
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS号151937-76-7 |
关联
38
项与 盐酸戊乙奎醚 相关的临床试验ChiCTR2500101199
The influence of penehyclidine hydrochloride on postoperative pulmonary complications in patients undergoing laparoscopic radical gastrectomy for gastric cancer
ChiCTR2500101387
Penehyclidine for prevention of postoperative nausea and vomiting in gynecological day surgery under remazolam-alfentanil general anesthesia: a randomized, double-blind, positive-controlled study
NCT06624696
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia: a Double-blind, Randomized, Placebo-controlled Trial
100 项与 盐酸戊乙奎醚 相关的临床结果
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的转化医学
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的专利（医药）
登录后查看更多信息
665
项与 盐酸戊乙奎醚 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Study on the mechanism of action of Penehyclidine hydrochloride on LPS-induced acute lung injury by regulating autophagy through the mTOR/Keap1/Nrf2 signaling pathway
Article
作者: Weng, Shuoyun ; Chen, Zhicheng ; Huang, Shanjiao ; Liu, Danjuan ; Weng, Junting ; Guo, Rongjie ; Shi, Bingbing
Acute lung injury (ALI) is a clinical syndrome characterized by pulmonary inflammation and edema, leading to impaired oxygenation and respiratory failure. Penehyclidine hydrochloride (PHC) has anticholinergic, anti-inflammatory, and antioxidant properties. In this paper, we investigated the protective role of PHC in ALI and explored its mechanism of action. Both in vivo and in vitro experiments were performed using LPS induction to establish an ALI model. Following PHC intervention, the assessment of lung injury was conducted using pathological section examination, mouse lung injury scoring, and ELISA to measure oxidative stress markers including myeloperoxidase (MPO), malondialdehyde (MDA), Super Oxide Dismutase (SOD), and Glutathione Peroxidase (GSH-Px), as well as inflammatory cytokine levels of TNF-α, IL-1β, and IL-18. Immunoblotting and immunofluorescence assays were employed to detect autophagy markers and the mTOR/Keap1/Nrf2 signaling pathway. To confirm the role of autophagy in the protective effects of PHC against ALI, we administered PHC in combination with Rapamycin (RAPA) or 3-Methyladenine (3-MA) to the model groups and evaluated the aforementioned parameters. Our findings revealed that in the LPS-induced ALI model, there was significant pulmonary histopathological damage and increased levels of MPO, MDA, TNF-α, IL-1β, and IL-18, along with decreased levels of SOD and GSH-Px in lung tissue or serum. These alterations were all reversed following PHC treatment. Additionally, compared to the ALI group, PHC administration reversed the expression of mTOR/Keap1/Nrf2 and autophagy proteins LC3, Beclin-1 and p62 induced by LPS. Treatment with the mTOR inhibitor (autophagy inducer RAPA) blocked the protective effects of PHC on lung injury, the mTOR/Keap1/Nrf2 signaling pathway, and autophagy, while co-treatment with the autophagy inhibitor 3-MA showed a significant protective effect on ALI. The results suggest that PHC has a notable protective effect on ALI, which may be achieved by modulating the mTOR/Keap1/Nrf2 signaling pathway to inhibit autophagy.
2025-05-01INTERNATIONAL IMMUNOPHARMACOLOGY
Rab32 protects mitochondrial function by anchoring Fancd2 and mediates the protective effect of penehyclidine hydrochloride against myocardial ischemia-reperfusion injury
Article
作者: Zhang, Kun ; Yu, JinGui ; Yang, Kehui ; Xiao, Yang ; Zeng, Lingyuan
Myocardial cell injury resulting from myocardial ischemia and reperfusion is one of the primary drivers behind the onset and progression of heart disease. Penehyclidine hydrochloride (PHC), a novel selective anti-cholinergic agent, exerts a protective effect against myocardial ischemia-reperfusion injury (MIRI). Rab32 belongs to the family of small GTPase proteins. The present study aimed to investigate whether PHC improved MIRI by regulating Rab32 and to explore the underlying mechanisms. Oxygen-glucose deprivation/reoxygenation (OGD/R) and left anterior descending coronary artery ligation were used to establish MIRI models in vitro and in vivo. Here, we showed that PHC upregulated the expression of Rab32 in OGD/R treated HL-1 cells. PHC alleviated OGD/R-induced cell apoptosis and intracellular and mitochondrial ROS levels, while the downregulation of Rab32 exacerbated cell injury. Rab32 was upregulated in MIRI mice and downregulated in OGD/R-induced HL-1 cells. Rab32 overexpression improved cardiac function, reduced the myocardial infarct size, and inhibited cell apoptosis and mitochondrial dysfunction, either in MIRI mice or OGD/R-induced HL-1 cells. On the mechanism, Rab32 interacted with Fancd2 in HL-1 cells. Rab32 downregulation decreased Fancd2 protein expression in mitochondria. Rab32 anchored Fancd2 to mitochondria in OGD/R treated HL-1 cells. Fancd2 knockdown reversed the protective effect of Rab32 on OGD/R-induced HL-1 cells and aggravated cardiomyocyte injury. Finally, the protective role of PHC on MIRI-caused cardiomyocyte injury was confirmed in MIRI mice. Overall, we demonstrated that Rab32 protects mitochondrial function by anchoring Fancd2 and mediates the protective effect of PHC against MIRI.
2025-02-01Journal of Anesthesia
Study of penehyclidine for the prevention of postoperative nausea and vomiting following laparoscopic sleeve gastrectomy under general anesthesia: a randomized, prospective, double-blind trial
Article
作者: Wang, Min ; Wu, Zhou-Quan ; Wang, Ting-Ting ; Liu, Chen
PURPOSE:
To investigate the efficacy of penehyclidine (PHC) for preventing postoperative nausea and vomiting (PONV) after laparoscopic sleeve gastrectomy (LSG) under general anesthesia.
MATERIALS AND METHODS:
In this prospective study, 219 patients who were scheduled to undergo LSG were randomly assigned to three cohorts: the control cohort (received normal saline), the infusion cohort (administered 0.25 mg of PHC intravenously followed by an additional 0.25 mg through an intravenous analgesia pump for 48 h after LSG), and the bolus cohort (received a single intravenous dose of 0.5 mg of PHC). The study outcomes included the incidence of PONV within the first 48 h postoperatively, the severity and intensity of PONV, side effects and postoperative recovery outcomes. Univariate and multivariate logistic analyses were performed to identify independent risk factors associated with PONV.
RESULTS:
PHC effectively prevented PONV occurrence and reduced its severity in LSG patients without decreasing postoperative recovery outcomes, particularly in the infusion cohort.
100 项与 盐酸戊乙奎醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2002-10-24 | |
| 药物中毒 | 中国 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆道痛 | 临床2期 | 中国 | 2017-05-19 | |
| 胆道痉挛 | 临床2期 | 中国 | 2017-05-19 | |
| 慢性阻塞性肺疾病 | 临床2期 | 中国 | 2008-07-21 | |
| 脓毒性休克 | 临床1期 | 中国 | 2012-06-11 | |
| 帕金森病 | 临床1期 | 中国 | 2012-03-15 | |
| 休克 | 临床1期 | 中国 | 2012-03-15 | |
| 平滑肌痉挛 | 临床1期 | 中国 | 2012-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | 願壓壓觸鬱鏇鑰淵齋壓(齋鹹製膚憲醖憲鹹齋醖) = 鏇壓醖獵鹽餘襯壓艱簾 構醖積觸獵繭憲膚餘願 (壓願積鹽鬱衊壓齋選廠 ) | - | 2022-10-14 | ||
TIVA group | 願壓壓觸鬱鏇鑰淵齋壓(齋鹹製膚憲醖憲鹹齋醖) = 夢遞選願窪襯願構鹹範 構醖積觸獵繭憲膚餘願 (壓願積鹽鬱衊壓齋選廠 ) | ||||||
临床3期 | - | 864 | 鹹蓋膚築鑰廠衊網鏇鑰(選觸構廠繭齋窪獵積廠) = dry mouth and delirium 鑰鬱選淵觸遞蓋顧艱選 (鹽構壓廠糧夢繭壓製積 ) | 积极 | 2022-04-01 | ||
Placebo | |||||||
临床4期 | 228 | 鹹鹽壓網蓋襯網網鹽蓋(遞積獵窪齋膚襯壓齋積) = 築鬱壓鏇簾襯膚網製糧 糧簾夢衊繭簾膚獵衊遞 (積顧窪範齋齋蓋醖醖齋 ) 更多 | - | 2021-02-13 | |||
鹹鹽壓網蓋襯網網鹽蓋(遞積獵窪齋膚襯壓齋積) = 膚網餘構壓觸蓋糧餘壓 糧簾夢衊繭簾膚獵衊遞 (積顧窪範齋齋蓋醖醖齋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用